Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia

Cancer

Volumn 119, Issue 15, 2013, Pages 2728-2736

  Kantarjian, Hagop ^a   Thomas, Deborah ^a   Jorgensen, Jeffrey ^a   Kebriaei, Partow ^a   Jabbour, Elias ^a   Rytting, Michael ^a   York, Sergernne ^a   Ravandi, Farhad ^a   Garris, Rebecca ^a   Kwari, Monica ^a   Faderl, Stefan ^a   Cortes, Jorge ^a   Champlin, Richard ^a   O'Brien, Susan ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

acute lymphocytic leukemia; inotuzumab; monoclonal antibody; refractory; relapsed

Indexed keywords

AMINOTRANSFERASE; AMYLASE; BILIRUBIN; INOTUZUMAB OZOGAMICIN; TRIACYLGLYCEROL LIPASE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; BONE MARROW; CANCER REGRESSION; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CHILD; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG CLEARANCE; DRUG INDUCED HEADACHE; DRUG INFUSION; DRUG SAFETY; DRUG TISSUE LEVEL; FEVER; FOLLOW UP; HUMAN; HYPOALBUMINEMIA; HYPOKALEMIA; HYPOTENSION; LEUKEMIA RELAPSE; LIVER FUNCTION; MAJOR CLINICAL STUDY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRESCHOOL CHILD; PRIORITY JOURNAL; SALVAGE THERAPY; SCHOOL CHILD; SIDE EFFECT; SINGLE DRUG DOSE; SURVIVAL RATE; SURVIVAL TIME; VEIN OCCLUSION;

ACUTE LYMPHOCYTIC LEUKEMIA; INOTUZUMAB; MONOCLONAL ANTIBODY; REFRACTORY; RELAPSED;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; CHILD; CHILD, PRESCHOOL; COMBINED MODALITY THERAPY; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RECURRENCE; SALVAGE THERAPY; SIALIC ACID BINDING IG-LIKE LECTIN 2; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84880574025     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.28136     Document Type: Article

References (14)

1. Gokbuget N, Hoelzer D, Arnold R, et al. Treatment of adult ALL according to protocols of the German Multicenter Study Group for Adult ALL (GMALL). Hematol Oncol Clin North Am. 2000; 14: 1307-1325.
2. Bassan R, Hoelzer D,. Modern therapy of acute lymphoblastic leukemia. J Clin Oncol. 2011; 29: 532-543.
3. Faderl S, O'Brien S, Pui CH, et al. Adult acute lymphoblastic leukemia. Cancer. 2010; 116: 1165-1176.
4. Thomas DA, Faderl S, O'Brien S, et al. Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. Cancer. 2006; 106: 1569-1580.
5. Gokbuget N, Hoelzer D,. Rituximab in the treatment of adult ALL. Ann Hematol. 2006; 85: 117-119.
6. Rizzieri D, Johnson J, Byrd J, et al. Efficacy and toxicity of rituximab and brief duration, high intensity chemotherapy with filgrastim support for Burkitt or Burkitt-like leukemia/lymphoma: Cancer and Leukemia Group B (CALGB) study 10002 [abstract]. Blood (ASH Annual Meeting Abstracts). 2010; 116. Abstract 858.
7. Thomas D, O'Brien S, Faderl S, et al. Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de-novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia. J Clin Oncol. 2010; 28: 3880-3889.
8. Hoelzer D, Huettmann A, Kaul F, et al. Immunochemotherapy with rituximab improves molecular CR rate and outcome in CD20+ B-lineage standard and high risk patients; results of 263 CD20+ patients studied prospectively in GMALL study 07/2003 [abstract]. Blood (ASH Annual Meeting Abstracts). 2020; 116. Abstract 170.
9. Raetz E, Cairo M, Borowitz M, Blaney S, et al. Chemoimmunotherapy reinduction with epratuzumab in children with acute lymphoblastic leukemia in marrow relapse: a Children's Oncology Group pilot study. J Clin Oncol. 2008; 26: 3756-3762.
10. Topp M, Kufer P, Gokbuget N, et al. Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. J Clin Oncol. 2011; 29: 2493-2498.
11. Thorson J, Sievers E, Ahlert J, et al. Understanding and exploiting nature's chemical arsenal: the past, present and future of calicheamicin research. Curr Pharm Des. 2000; 6: 1841-1879.
12. Kantarjian H, Thomas D, Jorgensen J, et al. Inotuzumab ozogamicin, an anti-CD22-calicheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study. Lancet Oncol. 2012; 13: 403-411.
13. O'Brien S, Thomas D, Ravandi F, et al. Outcome of adults with acute lymphocytic leukemia after second salvage therapy. Cancer. 2008; 113: 3186-3191.
14. Thomas D, Kantarjian H, Smith T, et al. Primary refractory and relapsed adult acute lymphoblastic leukemia. Cancer. 1999; 86: 1216-1230.